Novo Nordisk's Weight-Loss, Diabetes Drug Candidate Meets Primary Goals
MT Newswires Live
Sep 21
Novo Nordisk's (NVO) investigational once-weekly weight-loss and diabetes treatment CagriSema was superior to tirzepatide and met its primary superiority endpoint in two phase 3 trials, respectively, the company said Monday.
In one study, CagriSema achieved an average weight loss of 12.4%, compared with 9.1% for tirzepatide, the company said.
In the other study, CagriSema provided a weight reduction of 21% versus 2% for a placebo, the company said. CagriSema also showed improvements compared with the placebo in other prespecified supportive endpoints including blood pressure, waist-to-height ratio, and fasting lipid profile, the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.